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tion, drug cost, and therapeutic outcomes. Although
additional data is required for conclusive evidence, the
preliminary data suggests a downward trend in antibiotic
costs in the ICU.
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INTRODUCTION: The impact of prescription NSAIDS
on the GI tract is well documented. The easy availability
of low-dose OTC NSAIDs may lead to iatrogenic GI dis-
ease invisible to the medical community. OBJECTIVE:
To determine if the role and rate of GI adverse side ef-
fects were related to over-the-counter NSAID use. METH-
ODS: Data were obtained by structured telephone survey
administered to a nationally representative, randomly se-
lected US adult population (40 years). We compared re-
sponses of regular OTC NSAID users (defined as use for
at least 4 of 7 days, and 16 of 30 days prior to the sur-
vey) with those of non-users. Logistic regression com-
pared the likelihood of GI symptoms and use of GI med-
ications, after adjusting for age, gender, ethnicity, and
self-reported health status. RESULTS: We surveyed 535
OTC NSAID users (mean age  63, range 40–96) and
1068 non users (mean age  63, range 40–93). NSAID
users were 2.1 times more likely to report GI symptoms
than non users (P  0.0001), and 2.7 times more likely
to have taken OTC GI medications than non users (P 
0.0001) during past 30 days. 84.8% of NSAID users tak-
ing GI medications for their symptoms had not informed
a physician of GI symptoms. CONCLUSIONS: OTC
NSAIDs are widely used and thought to be safe at low
dose. Our data show users commonly experience GI
symptoms, for which they self-medicate without inform-
ing their physician. This may represent an important bur-
den of hidden GI disease.
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Peptic ulcers, erosions of the stomach lining, afflict greater
than 25 million Americans. Ulcers diminish quality of life
and cost nearly $6 billion dollars annually. OBJECTIVE:
To decrease unnecessary medical utilization, histamine-2-
blocker (H2) and proton-pump-inhibitor (PPI) utilization
and improve quality of life for peptic ulcer patients by us-
ing educational intervention to increase compliance to
drug regimens for H. pylori eradication. METHODS: Pa-
tients were targeted for specific antibiotic therapies via
drug data and verified at first telephone contact. A ques-
tionnaire developed and validated by Lewin-TAG was
used for data collection. Data were collected for a 90 day
period pre/post therapy regarding hospitalizations, doc-
tor visits, emergency room visits, lost productivity, out-
patient surgeries, pharmacy utilization and medical test/
procedures resulting from the disease. Quality of life
questions measured how often usual activities and work
productivity were reduced due to peptic ulcer disease. Pa-
tient satisfaction with the program was also measured.
RESULTS: (n  1993, response rate  94.5%) Patient
compliance to drug regimen was found to be 95.7%.
Hospitalizations were reduced by 73% (P  0.0001),
doctor visits by 49% (P  0.0001). Emergency room vis-
its were reduced by 72% (P  0.0001) and outpatient
surgeries by 56% (P  0.0001). Finally, a decrease of
54% in H2/PPI usage (P  0.0001) and a decrease of
76% in medical tests/procedures (P  0.0001) were seen.
Participants reported a 13% decrease in pain and symp-
toms (P  0.005) and a 34% increase in productivity
(P  0.0001). Participant satisfaction rate with the pro-
gram was 98.6%. CONCLUSION: The CarePatterns
peptic ulcer disease program improves patients’ quality
of life, reduces unnecessary medical and pharmacy utili-
zation, and is cost-effective.
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OBJECTIVE: The aim of this project is to evaluate the ef-
fectiveness of a program including practice guidelines,
treatment algorithms, and peer comparison feedback in
changing physicians’ prescribing behaviors in the treat-
ment of patients with peptic ulcer disease (PUD). METH-
ODS: A prospective intervention with a control group
was conducted to determine the impact of a PUD infor-
mation dissemination program targeted towards physi-
cians in a managed care setting. Pharmacy claims data
were used to assess impact of the program on utilization
of eradication therapy, long-term antisecretory utiliza-
tion, and total cost of drug therapy per patient. RE-
SULTS: Preliminary data from a 3-month follow-up pe-
riod are available and indicate that utilization of eradication
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therapy increased significantly for physicians in the inter-
vention group compared to physicians in the control
group during the post-intervention period (P  0.02).
This increase in eradication utilization was not accompa-
nied by a significant increase in the total cost of drug
therapy per patient for the intervention group compared
to the control group (P  0.82). The results from a 9-month
follow-up period will be presented. CONCLUSIONS:
The main goal of the study, to increase the utilization of
eradication therapy, was achieved in the 3-month follow-
up period. Observable modification of physician behav-
ior in only a three-month period is a positive finding, and
may indicate an even greater impact when the program is
evaluated over a longer period of time.
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OBJECTIVES: The optimal management strategy for pa-
tients with symptoms of GERD remains undefined. Our
objective was to examine the clinical and economic im-
pact of competing management strategies. METHODS:
Decision analysis was used to compare a traditional
“step-up” strategy with sequential invasive diagnostic
testing as needed to a strategy utilizing the initial “PPI
test” followed by a “step-down” approach with sequen-
tial diagnostic testing as needed. The cost per symptom-
free patient was assessed at 1-year. Systematic literature
review, Medicare payments and drug AWPs were used to
derive probability and cost estimates for the model.
Where there was uncertainty in the literature, estimates
were chosen to bias the model in favor of the traditional
management strategy. RESULTS: The average cost per
patient was $1045 and $1172 for the traditional “step-
up” and PPI test strategies, respectively. The percentage
of patients symptom-free at 1 year was 50% and 75%
for the traditional and PPI test strategies, respectively.
The incremental cost-effectiveness ratio for the PPI test
strategy was $510 per additional symptomatic cure. The
traditional strategy resulted in a greater than 5-fold in-
crease in endoscopy utilization but a 47% reduction in
ambulatory pH monitoring use. The reduced effective-
ness of the traditional strategy may be attributed to a
118% increase in the use of high-dose H2RAs while re-
ducing the use of PPIs by 42%–57%. The PPI test strat-
egy remained most cost-effective as long as the sensitivity
of the PPI test was greater than 23% and more than 47%
of patients with a positive PPI test received a “step-
down” trial. CONCLUSIONS: Strategies utilizing the
initial PPI test followed by a “step-down” approach may
result in improved symptom relief over 1 year, and more
appropriate utilization of invasive diagnostic testing at a
small marginal cost increase. These findings warrant a
prospective trial comparing these strategies.
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Recent work has shown that screening for Hepatitis C is
cost-effective from a societal perspective. Safety-net hos-
pitals are committed to providing care for their many un-
insured and underinsured patients who are unable to
pay. Adopting a screening policy would commit the insti-
tution to pay for expensive treatment for many of the
screened positives. OBJECTIVE: Examine the economic
implications for a safety-net hospital that adopts a Hepa-
titis C screening policy. METHODS: A Markov decision
analytic model was constructed, using a reference case of
a 35 year-old male without symptoms of Hepatitis C. The
perspective adopted was a safety-net hospital. Two popu-
lations were examined: uninsured, and insured, but with-
out coverage for combination interferonribavirin. Screen-
ing consisted of ELISA followed by a confirmatory PCR.
It was assumed that PCR and virus genotyping were sent
to an outside laboratory. Data came from prior publica-
tions. Patients were considered to be patients of this facility
for 5 years. RESULTS: In the uninsured group, screening
costs an additional $245 per patient, with an incremental
cost-effectiveness ratio (ICER) of $12,300/QALY. As
prevalence of infection ranged from 0.8%–9%, the addi-
tional cost of screening ranged from $77–$587, and the
ICER from $11,500/QALY–$16,800/QALY. In the under-
insured group, screening was associated with an addi-
tional cost of $166 per patient, with an ICER of $8300/
QALY. Varying the prevalence produced additional costs
of $38–$427. CONCLUSIONS: Although ICERs would
appear to be cost-effective from a societal perspective,
this is less clear for hospitals that deal with hard budgets,
not the soft budget, cost-conscious environment assumed
by incremental cost-effectiveness analysis. Screening for
Hepatitis C may be an expensive policy to implement for
safety-net hospitals. Public funding to support a screen-
ing and treatment program may be well justified.
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